Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPB898 (Nivolumab Biosimilar) vs Opdivo in Advanced Melanoma
NCT06587451Phase 3Terminated
- Sponsor
- Sandoz
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Countries
- 11
01
Overview
A Phase 3 trial of LY01015 in melanoma, sponsored by Sandoz. Started Dec 2024; status: terminated.
02
Drugs
LY01015
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06587451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06587451.